Sionna Therapeutics (NASDAQ:SION) Earns Outperform Rating from Analysts at Lifesci Capital

Lifesci Capital began coverage on shares of Sionna Therapeutics (NASDAQ:SION) in a research report sent to investors on Tuesday, Marketbeat reports. The firm issued an outperform rating and a $60.00 price target on the stock. Lifesci Capital also issued estimates for Sionna Therapeutics’ FY2025 earnings at ($1.74) EPS, FY2026 earnings at ($2.29) EPS, FY2027 earnings at ($3.58) EPS, FY2028 earnings at ($4.63) EPS and FY2029 earnings at ($4.03) EPS.

SION has been the topic of several other research reports. Wall Street Zen raised Sionna Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, December 13th. BTIG Research initiated coverage on Sionna Therapeutics in a research report on Wednesday, November 19th. They set a “buy” rating and a $50.00 target price on the stock. Raymond James Financial reaffirmed a “strong-buy” rating on shares of Sionna Therapeutics in a research report on Wednesday, November 5th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Sionna Therapeutics in a research note on Monday, December 15th. Finally, Jones Trading initiated coverage on Sionna Therapeutics in a report on Monday, September 8th. They set a “buy” rating and a $46.00 target price on the stock. Two research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Sionna Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $43.14.

Sionna Therapeutics Price Performance

SION opened at $44.03 on Tuesday. Sionna Therapeutics has a 12 month low of $7.26 and a 12 month high of $45.00. The stock has a market capitalization of $1.97 billion and a P/E ratio of -9.04. The business has a 50 day simple moving average of $39.82 and a 200-day simple moving average of $28.02.

Sionna Therapeutics (NASDAQ:SION) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.06.

Insiders Place Their Bets

In other news, Director Orbimed Advisors Llc sold 875 shares of the firm’s stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $44.49, for a total value of $38,928.75. Following the transaction, the director directly owned 3,595,011 shares in the company, valued at approximately $159,942,039.39. This trade represents a 0.02% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Peter A. Thompson sold 875 shares of the stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $44.49, for a total transaction of $38,928.75. Following the sale, the director owned 3,595,011 shares in the company, valued at approximately $159,942,039.39. This trade represents a 0.02% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 1,591,384 shares of company stock worth $57,982,534 over the last three months. 3.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Sionna Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Millennium Management LLC lifted its stake in Sionna Therapeutics by 1,425.5% in the third quarter. Millennium Management LLC now owns 214,085 shares of the company’s stock valued at $6,296,000 after buying an additional 200,051 shares during the last quarter. Jain Global LLC acquired a new stake in shares of Sionna Therapeutics in the 3rd quarter worth about $250,000. Bank of America Corp DE lifted its position in Sionna Therapeutics by 8.8% in the 3rd quarter. Bank of America Corp DE now owns 6,541 shares of the company’s stock valued at $192,000 after purchasing an additional 529 shares during the last quarter. Longaeva Partners L.P. acquired a new position in Sionna Therapeutics during the 3rd quarter valued at about $1,807,000. Finally, Squarepoint Ops LLC bought a new position in Sionna Therapeutics in the 3rd quarter worth about $299,000.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.